07-05-2025
Analysts Offer Insights on Healthcare Companies: BioAge Labs, Inc. (BIOA) and Immutep Ltd (OtherPRRUF)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on BioAge Labs, Inc. (BIOA – Research Report) and Immutep Ltd (PRRUF – Research Report).
Protect Your Portfolio Against Market Uncertainty
Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
BioAge Labs, Inc. (BIOA)
In a report released today, Andy Hsieh from William Blair reiterated a Hold rating on BioAge Labs, Inc.. The company's shares closed last Tuesday at $3.95, close to its 52-week low of $3.80.
According to Hsieh is a 4-star analyst with an average return of 6.0% and a 43.7% success rate. Hsieh covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Barinthus Biotherapeutics, and Corbus Pharmaceuticals.
BioAge Labs, Inc. has an analyst consensus of Hold, with a price target consensus of $5.67.
Immutep Ltd (PRRUF)
In a report released today, Thomas Wakim from Bell Potter maintained a Buy rating on Immutep Ltd, with a price target of A$0.70. The company's shares closed last Monday at $0.22.
According to Wakim is a 1-star analyst with an average return of -6.9% and a 40.0% success rate. Wakim covers the Healthcare sector, focusing on stocks such as Neuren Pharmaceuticals Limited, Clinuvel Pharmaceuticals, and Opthea.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Immutep Ltd with a $0.98 average price target.
